Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject						
to Section 16. Form 4 or Form 5						
obligations may continue. See						

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Justice Angela				2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR ]									(Chec	ationship of Reportir k all applicable) Director Officer (give title		10% Own Other (sp		wner		
(Last) (First) (Middle) C/O TCR2 THERAPEUTICS 100 BINNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 12/09/2022									X	below) below)  Chief People Officer					
(Street) CAMBF (City)		MA State)	02142 (Zip)											6. Indi	Form	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson				
		Та	ble I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefi	icially	/ Own	ed				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction D		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securit Benefic Owned		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) (D)	or Pri	ce	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock															5′	7,365	D			
Common	mmon Stock 12/09/			:022			S <sup>(1)</sup>		2,792	D	\$1	1.128	28 54,573		D					
Common	Stock			12/12/2	2022				<b>S</b> <sup>(1)</sup>		2,865	D	\$1	1.099	.099 51,708 D					
Common	ommon Stock 12/12/20					2022		<b>S</b> <sup>(1)</sup>		2,963	D	\$1	1.063	063 48,745		45 D				
			Table II								osed of, convertib				Owne	d				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any			4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration			Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form Direct or Inc (I) (In		11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

## Remarks:

/s/ Margaret Siegel as Attorney-in-Fact

12/13/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.